SCHEMBL1748342

SCHEMBL1748342

CC(C)(C)OC(=O)N1CCN(c2ccc(S(C)(=O)=O)c(NCc3cc(Cl)cc(Cl)c3)c2)CC1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.52
HTT P42858 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
STS P08842 3/20 0.48
GPR119 Q8TDV5 5/20 0.47
CYP2C19 P33261 1/20 0.46
MAPT P10636 4/20 0.44
LMNA P02545 3/20 0.44
ALDH1A1 P00352 1/20 0.43
ACHE P22303 1/20 0.42
P2RX7 Q99572 2/20 0.42
POLB P06746 1/20 0.42
RECQL P46063 1/20 0.42
BLM P54132 1/20 0.42
ALK Q9UM73 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5283022 0.87 MAPT (0.45) SMN1; SMN2HTTNPSR1MEN1KMT2A
SCHEMBL5021177 0.83 HTR6 (0.59) SMN1; SMN2HTTNPSR1MEN1KMT2A
SCHEMBL1748702 0.83 SMN1; SMN2 (0.50) SMN1; SMN2HTTNPSR1MEN1KMT2A
SCHEMBL1748256 0.80 HTR6 (0.54) HTTCYP2C19MAPTLMNAALDH1A1
Hydrochloric Acid SCHEMBL1748665 0.79 HTR6 (0.53) HTTCYP2C19MAPTLMNAALDH1A1
SCHEMBL30516367 0.77 SMN1; SMN2 (0.46) SMN1; SMN2HTTNPSR1MEN1KMT2A
SCHEMBL21301974 0.77 SMN1; SMN2 (0.46) SMN1; SMN2HTTNPSR1MEN1KMT2A
SCHEMBL1748054 0.76 MAPT (0.58) HTTNPSR1CYP2C19MAPTLMNA
SCHEMBL23784871 0.75 MAPT (0.57) SMN1; SMN2HTTNPSR1MEN1KMT2A
SCHEMBL5280864 0.75 SMN1; SMN2 (0.47) SMN1; SMN2HTTNPSR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8604021-B2 Substituted arylamine compounds and methods of treatment BECKER OREN (IL) 2013-12-10 US disclosed
US-20120115850-A1 SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT BECKER OREN (IL) 2012-05-10 US disclosed
US-20120115850-A1 SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT BECKER OREN (IL) 2012-05-10 US disclosed
US-20120115850-A1 SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT BECKER OREN (IL) 2012-05-10 US disclosed
US-7968538-B2 Substituted arylamine compounds and methods of treatment GALENEA CORP. (US) 2011-06-28 US disclosed
US-7968538-B2 Substituted arylamine compounds and methods of treatment GALENEA CORP. (US) 2011-06-28 US disclosed
US-7968538-B2 Substituted arylamine compounds and methods of treatment GALENEA CORP. (US) 2011-06-28 US disclosed
US-20060205737-A1 Substituted arylamine compounds and methods of treatment GALENEA CORPORATION 2006-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115850-A1 SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT HTR6, HTR2A, HTR3B SMN1; SMN2 3858/4885HTT 375/4885NPSR1 128/4885
US-20060205737-A1 Substituted arylamine compounds and methods of treatment HTR6, HTR2A, HTR3B SMN1; SMN2 3858/4885HTT 375/4885NPSR1 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.